Skip to main content
. 2026 Oct 2;11(5):591–599. doi: 10.5194/jbji-11-591-2026

Table 2.

Univariable analysis of factors associated with DAIR failure.

Categorical variables
 
Failure n/N  (%)
No failure n/N  (%)
OR (95 % CI)
p  value
Male sex 52/91  (57.1) 39/91  (42.9) 0.80 (0.5–1.4) 0.438
Charlson Comorbidity Index ≥ 3 18/23  (78.3) 5/23  (21.7) 3.39 (1.2–9.5) 0.015
CRP > 150 mg L−1 32/46  (69.6) 14/46  (30.4) 2.29 (1.1–4.6) 0.021
Bacteraemia 12/17  (70.6) 5/17  (29.4) 2.13 (0.7–6.3) 0.161
Fracture indication 31/60  (51.7) 29/60 (48.3) 0.88 (0.5–1.6) 0.669
Revision prosthesis 51/71  (71.8) 20/71  (28.2) 3.02 (1.6–5.5) <0.001
Cemented prosthesis 75/142  (52.8) 67/142  (47.2) 0.67 (0.3–1.3) 0.243
Hip PJI 67/117  (57.3) 50/117  (42.7) 1.34 (0.8–2.3) 0.277
Gram-negative infection 28/42  (66.7) 14/42  (33.3) 1.90 (0.9–3.9) 0.068
Polymicrobial infection
17/25  (68.0)
8/25  (32.0)
1.90 (0.8–4.7)
0.137
Continuous variables
 
Failure median (IQR)
No failure median (IQR)
p  value
 
Age (years) 70 (63–79) 70 (65–77) 0.545  
Charlson Comorbidity Index 1 (0–1) 1 (0–1) 0.098  
Haemoglobin (g dL−1) 10.5 (9.4–11.6) 10.6 (9.5–11.6) 0.457  
Leucocyte count (cell mm−3) 8250 (6420–11 570) 8780 (6503–12 615) 0.920  
CRP (mg L−1) 77.5 (27–187) 61.5 (23–133) 0.023  
Time from index arthroplasty to DAIR (days) 43 (27–208) 31 (20–39) <0.001  

Denominators vary due to missing data and are shown where applicable. CRP: C-reactive protein; DAIR: debridement, antibiotics, and implant retention.